MX2022015253A - Moleculas peque?as novedosas para la degradacion dirigida de kras no dirigibles en la terapia contra el cancer. - Google Patents

Moleculas peque?as novedosas para la degradacion dirigida de kras no dirigibles en la terapia contra el cancer.

Info

Publication number
MX2022015253A
MX2022015253A MX2022015253A MX2022015253A MX2022015253A MX 2022015253 A MX2022015253 A MX 2022015253A MX 2022015253 A MX2022015253 A MX 2022015253A MX 2022015253 A MX2022015253 A MX 2022015253A MX 2022015253 A MX2022015253 A MX 2022015253A
Authority
MX
Mexico
Prior art keywords
group bonded
carbonyl
alkyl group
untargetable
kras
Prior art date
Application number
MX2022015253A
Other languages
English (en)
Spanish (es)
Inventor
M G Dinesh
Dr Baskaran Pillai
Original Assignee
Pillai Universal Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pillai Universal Llc filed Critical Pillai Universal Llc
Publication of MX2022015253A publication Critical patent/MX2022015253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
MX2022015253A 2020-06-04 2021-05-26 Moleculas peque?as novedosas para la degradacion dirigida de kras no dirigibles en la terapia contra el cancer. MX2022015253A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202041023434 2020-06-04
PCT/IB2021/054591 WO2021245499A1 (en) 2020-06-04 2021-05-26 Novel small molecules for targeted degradation of untargetable kras in cancer therapy

Publications (1)

Publication Number Publication Date
MX2022015253A true MX2022015253A (es) 2023-03-14

Family

ID=78830675

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015253A MX2022015253A (es) 2020-06-04 2021-05-26 Moleculas peque?as novedosas para la degradacion dirigida de kras no dirigibles en la terapia contra el cancer.

Country Status (12)

Country Link
US (1) US20230202981A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161511B1 (cg-RX-API-DMAC7.html)
JP (1) JP7789016B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230019937A (cg-RX-API-DMAC7.html)
CN (2) CN115768427B (cg-RX-API-DMAC7.html)
AU (1) AU2021284517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024300A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180686A1 (cg-RX-API-DMAC7.html)
IL (1) IL298672A (cg-RX-API-DMAC7.html)
MX (1) MX2022015253A (cg-RX-API-DMAC7.html)
TW (1) TWI916370B (cg-RX-API-DMAC7.html)
WO (1) WO2021245499A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
WO2025083564A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small molecule degrader as a potential anticancer
WO2025083561A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel lead small molecule inhibitors on undruggable target towards anticancer activity
WO2025083570A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small-molecule agents in overcoming tumor regression in cancers
WO2025083563A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Effective therapeutic small-molecule inhibitors for metastatic cancer
WO2025083568A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small-molecule protein kinase inhibitors for implications in cancer treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3347A1 (fr) * 2000-05-22 2001-11-29 Aventis Pharma Inc Dérivés d'arylméthylamine pour leur utilisation comme inhibiteurs de la tryptase
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
IL161662A0 (en) * 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
CA2795952A1 (en) * 2010-04-16 2011-10-20 Curis, Inc. Treatment of cancers having k-ras mutations
US20190284149A1 (en) * 2014-09-12 2019-09-19 Ariagen, Inc. Aryl hydrocarbon receptor modulator
CN106317055A (zh) * 2015-07-02 2017-01-11 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
EP3573971A1 (en) * 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110885332B (zh) * 2019-12-06 2022-03-18 中国人民解放军第二军医大学 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用

Also Published As

Publication number Publication date
KR20230019937A (ko) 2023-02-09
EP4161511B1 (en) 2026-04-29
TWI916370B (zh) 2026-03-01
IL298672A (en) 2023-01-01
BR112022024300A2 (pt) 2023-01-24
CA3180686A1 (en) 2021-12-09
CN115768427B (zh) 2025-03-28
CN115768427A (zh) 2023-03-07
US20230202981A1 (en) 2023-06-29
WO2021245499A1 (en) 2021-12-09
JP7789016B2 (ja) 2025-12-19
EP4161511A1 (en) 2023-04-12
JP2023529354A (ja) 2023-07-10
CN120208921A (zh) 2025-06-27
TW202210465A (zh) 2022-03-16
EP4161511A4 (en) 2024-07-17
AU2021284517A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
BR112022024300A2 (pt) Moléculas pequenas para degradação direcionada de kras não direcionado na terapia de câncer
CR20230286A (es) Inhibidores de prmt5 novedosos
CL2023001738A1 (es) Inhibidores de prmt5
JP2023529354A5 (cg-RX-API-DMAC7.html)
IL261852A (en) Substituted imidazole based compounds for treatment of cancer
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
CY1113538T1 (el) Παραγωγα της 5-αμινο-2,4,7-τριοξο-3,4,7,8-τετραϋδρο-2η-πυριδο[2,3-d] πυριμιδινης και παρομοιες ενωσεις για την αγωγη του καρκινου
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
SMT201300096B (it) Inibitori di prolil idrossilasi
RU2015143841A (ru) Ингибиторы hdac
US20140335018A1 (en) Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
JP2019069969A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ2a阻害剤
RU2013112871A (ru) Соединения для лечения рака
WO2012047630A2 (en) N-alkyl or n-aryl substituted guanide and biguanide compounds and methods of their use
EA200800516A1 (ru) Производные n-фенил-2-пиримидинамина и процесс их получения
MX2019010096A (es) Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
WO2020141923A3 (ko) 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
MX2025005223A (es) Agonistas del estimulador de genes de interferon (sting)
JOP20250214A1 (ar) مشتقات هيدروكينازولين لعلاج مرض أو اضطراب
MX2024002674A (es) Derivados de tiadiazolona utiles como activadores de ampk.
MX2024012967A (es) Derivados de piridina para el tratamiento de los trastornos psiquiatricos
MX2024000610A (es) Compuestos terapeuticos y procedimientos.
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
ZA202102241B (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety